Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2

Ryan C Henrici, PhD BS, Casey Sautter, MDMS, Robert Opoka, MMED, Ruth Namazzi, MD, Gregory S Park, Dibyadyuti John, PhD, Andrea L Conroy, PhD, Russell E. Ware, MD PhD, Chandy C. John, MDMS

Blood (2019) 134 (Supplement_1): 2283.

https://doi.org/10.1182/blood-2019-129566

Published: 2019

Journal Articles

Orosomucoid As a Biomarker for Chronic Kidney Disease Associated with Sickle Cell Anemia

Ammanuel Taye, Nathan Smith, Nowah Kokou Apeadoufia Afangbedji, Xiaomei Niu, MD, James G. Taylor, MD, Marina Jerebtsova, PhD, Sergei Nekhai, PhD

Blood (2018) 132 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2018-99-119477

Published: 2018

Journal Articles

The Predictive Value of Intracellular Imatinib Levels in Chronic Myeloid Leukemia

Nicholas L Jackson Chornenki, BSc, Christopher M. Hillis, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Caroline Hamm, MD, Wanda Hasegawa, MD, Jeffrey H. Lipton, MD PhD, Lynn Savoie, MD, Robert Turner, MD, Anargyros Xenocostas, MD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2018) 132 (Supplement 1): 4250.

https://doi.org/10.1182/blood-2018-99-111294

Published: 2018

Journal Articles

Combinatorial Approaches to Overcome Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

David J Young, MD PhD, Jun O Liu, PhD, Donald Small, MD PhD

Blood (2018) 132 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2018-99-118820

Published: 2018

Journal Articles

A Novel Method for Overcoming Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

David J Young, MD PhD, Donald Small, MD PhD

Blood (2017) 130 (Supplement 1): 1241.

https://doi.org/10.1182/blood.V130.Suppl_1.1241.1241

Published: 2017

Journal Articles

Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia

Sara Galimberti, MD, Laura Galeotti, Francesco Ceccherini, Dario Domingo, Marco Laurino, Marialuisa Polillo, Antonello Di Paolo, Claudia Baratè, MD, Carmen Fava, MD, Antonio D'Avolio, Giulia Fontanelli, Romano Danesi, Fulvio Cornolti, Francesca Guerrini, Elena Ciabatti, Giuseppe Saglio, MDPhD, Mario Petrini

Blood (2015) 126 (23): 4838.

https://doi.org/10.1182/blood.V126.23.4838.4838

Published: 2015

Journal Articles

Mass Spectrometry of Urine Proteins for Early Detection of Renal Complications in Sickle Cell Disease

Elena A Adjei, BS, Namita Kumari, PhD

Blood (2014) 124 (21): 2714.

https://doi.org/10.1182/blood.V124.21.2714.2714

Published: 2014

Journal Articles

A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential

Blood (2014) 123 (5): 777–785.

https://doi.org/10.1182/blood-2013-10-529628

Published: 2014

Includes: Supplemental data

Journal Articles

Go6976, a Potent FLT3 Kinase Inhibitor, Exerts Antiproliferative Activity Against Acute Myeloid Leukemia Via Inhibition Of Survivin and Mcl-1 In The Presence Of Human Serum

Akira Yoshida, MD, PhD, Kouichi Zokumasu, Takanori Ueda, MD, PhD

Blood (2013) 122 (21): 3839.

https://doi.org/10.1182/blood.V122.21.3839.3839

Published: 2013

Journal Articles

Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants

Joseph M Gozgit, PhD, Alexa Schrock, PhD, Tzu-Hsiu Chen, Tim Clackson, PhD, Victor M. Rivera, PhD

Blood (2013) 122 (21): 3992.

https://doi.org/10.1182/blood.V122.21.3992.3992

Published: 2013

Journal Articles

Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM)

Brian Tunquist, Karin Brown, Gary Hingorani, Sagar Lonial, MD, Jonathan L. Kaufman, MD, Jeffrey A. Zonder, MD, Adam D Cohen, MD, William I. Bensinger, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D., Brandi Hilder, Ann Marie Ptaszynski, MD, Kevin Koch, Kevin Litwiler, Duncan Walker

Blood (2012) 120 (21): 1868.

https://doi.org/10.1182/blood.V120.21.1868.1868

Published: 2012

Journal Articles

TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia

Hayley S Wall, B.S., Bao Nguyen, M.S., Li Li, PhD, Sarah M Greenblatt, PhD, Patrick Brown, MD, Mark J. Levis, MD, PhD, Donald Small, MD, PhD

Blood (2012) 120 (21): 866.

https://doi.org/10.1182/blood.V120.21.866.866

Published: 2012

Journal Articles

The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials

Steven Knapper, DM MRCP FRCPath, Paul White, PhD, Mark J. Levis, MD, PhD, Robert K Hills, MA, MSc, DPhil, Nigel H. Russell, MD, Alan Burnett, MD, ChB, FRCP, FRCPath, FMedSci

Blood (2011) 118 (21): 421.

https://doi.org/10.1182/blood.V118.21.421.421

Published: 2011

Journal Articles

Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).

Sophie Dupire, Houria Debarri, Laurent Pascal, Valerie Coiteux, Benedicte Hivert, Christophe Willekens, Julien Rossignol, Ibrahim Yakoub-Agha, MD, PhD, Brigitte Onraed, Jean-Luc Faucompré, Bernadette Hennache, Charles Dumontet, Thierry Facon, Xavier Leleu

Blood (2009) 114 (22): 2493.

https://doi.org/10.1182/blood.V114.22.2493.2493

Published: 2009

Journal Articles

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Blood (2009) 114 (22): 788.

https://doi.org/10.1182/blood.V114.22.788.788

Published: 2009

Journal Articles

Serum α1-Acid Glycoprotein Level Associate with Imatinib Trough Plasma Concentration and Clinical Outcome in CML Patients Treated with Imatinib: Blood Level Testing of Imatinib in Nagoya (BINGO) Study.

Yuichi Ishikawa, MD, PhD, Hitoshi Kiyoi, MD, PhD, Keisuke Watanabe, MD, Yasuyuki Nakano, MD, PhD, Kunio Kitamura, MD, PhD, Akio Kohno, MD, PhD, Toshiya Yokozawa, MD, PhD, Isamu Sugiura, MD, PhD, Akitoshi Hanamura, MD, PhD, Hiroatsu Iida, MD, PhD, Kazuhito Yamamoto, MD, PhD, Ritsuro Suzuki, MD, PhD, Koichi Miyamura, MD, PhD, Nobuhiko Emi, MD, PhD, Kazunori Ohnishi, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2009) 114 (22): 4266.

https://doi.org/10.1182/blood.V114.22.4266.4266

Published: 2009

Journal Articles

Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.

F. Heidel, F. Breitenbuecher, T. Kindler, F. K. Solem, B. Carius, H.-M. Thiede, P. S. Cohen, J. Roesel, E. H. Estey, E. Feldman, G. Ehninger, G. J. Schiller, V. Klimek, S. Nimer, D. DeAngelo, F. Giles, R. M. Stone, C. Huber, T. Fischer

Blood (2004) 104 (11): 454.

https://doi.org/10.1182/blood.V104.11.454.454

Published: 2004

Journal Articles

Increased Susceptibility in Hp Knockout Mice During Acute Hemolysis

Sai-Kiang Lim, Hongkyun Kim, Shen Kiat Lim, Azhar bin Ali, Yew Koon Lim, Yanping Wang, Siew Meng Chong, Frank Costantini, Heinz Baumman

Blood (1998) 92 (6): 1870–1877.

https://doi.org/10.1182/blood.V92.6.1870

Published: 1998

Journal Articles

The in vivo metabolism of recombinant human erythropoietin in the rat

JL Spivak, BB Hogans

Blood (1989) 73 (1): 90–99.

https://doi.org/10.1182/blood.V73.1.90.90

Published: 1989

NARROW

Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2

Orosomucoid As a Biomarker for Chronic Kidney Disease Associated with Sickle Cell Anemia

The Predictive Value of Intracellular Imatinib Levels in Chronic Myeloid Leukemia

Combinatorial Approaches to Overcome Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

A Novel Method for Overcoming Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia

Mass Spectrometry of Urine Proteins for Early Detection of Renal Complications in Sickle Cell Disease

A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential

Go6976, a Potent FLT3 Kinase Inhibitor, Exerts Antiproliferative Activity Against Acute Myeloid Leukemia Via Inhibition Of Survivin and Mcl-1 In The Presence Of Human Serum

Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants

Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM)

TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia

The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials

Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Serum α1-Acid Glycoprotein Level Associate with Imatinib Trough Plasma Concentration and Clinical Outcome in CML Patients Treated with Imatinib: Blood Level Testing of Imatinib in Nagoya (BINGO) Study.

Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.

Increased Susceptibility in Hp Knockout Mice During Acute Hemolysis

The in vivo metabolism of recombinant human erythropoietin in the rat

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only